Importantly, the expression levels of GBP5 showed a significant positive correlation with CD8+ T cell infiltration levels (Figure 10F), corroborating our findings that ITRGM, which includes seven model genes, notably GBP5, is a promising biomarker for immunotherapy in melanoma. This evidence concerns the gene CD8A and melanoma.